Three UH researchers are revolutionizing the way we think the brain works. Andriy Onufriyenko/Getty Images

While a lot of scientists and researchers have long been scratching their heads over complicated brain functionality challenges, these three University of Houston researchers have made crucial discoveries in their research.

From dissecting the immediate moment a memory is made or incorporating technology to solve mobility problems or concussion research, here are the three brain innovations and findings these UH professors have developed.

Brains on the move

Professor of biomedical engineering Joe Francis is reporting work that represents a significant step forward for prosthetics that perform more naturally. Photo courtesy of UH Research

Brain prosthetics have come a long way in the past few years, but a UH professor and his team have discovered a key feature of a brain-computer interface that allows for an advancement in the technology.

Joe Francis,a UH professor of biomedical engineering, reported in eNeuro that the BCI device is able to learn on its own when its user is expecting a reward through translating interactions "between single-neuron activities and the information flowing to these neurons, called the local field potential," according to a UH news release. This is all happening without the machine being specifically programmed for this capability.

"This will help prosthetics work the way the user wants them to," says Francis in the release. "The BCI quickly interprets what you're going to do and what you expect as far as whether the outcome will be good or bad."

Using implanted electrodes, Francis tracked the effects of reward on the brain's motor cortex activity.

"We assume intention is in there, and we decode that information by an algorithm and have it control either a computer cursor, for example, or a robotic arm," says Francis in the release.

A BCI device would be used for patients with various brain conditions that, as a result of their circumstances, don't have full motor functionality.

"This is important because we are going to have to extract this information and brain activity out of people who cannot actually move, so this is our way of showing we can still get the information even if there is no movement," says Francis.

Demystifying the memory making moments

Margaret Cheung, a UH professor, is looking into what happens when a memory is formed in the brain. Photo courtesy of UH Research

What happens when a brain forms a new memory? Margaret Cheung, a UH professor in the school of physics, computer science, and chemistry, is trying to find out.

Cheung is analyzing the exact moment a neuron forms a memory in our brains and says this research will open doors to enhancing memory making in the future.

"The 2000 Nobel laureate Eric Kandel said that human consciousness will eventually be explained in terms of molecular signaling pathways. I want to see how far we can go to understand the signals," says Cheung in a release.

Cheung is looking at calcium in particular, since this element impacts most of cellular life.

"How the information is transmitted from the calcium to the calmodulin and how CaM uses that information to activate decisions is what we are exploring," says Cheung in the release. "This interaction explains the mechanism of human cognition."

Her work is being funded by a $1.1 million grant from the National Institute of General Medical Science from the National Institutes of Health, and she's venturing into uncharted territories with her calcium signaling studies. Previous research hasn't been precise or conclusive enough for real-world application.

"In this work we seek to understand the dynamics between calcium signaling and the resulting encoded CaM states using a multiphysics approach," says Cheung. "Our expected outcome will advance modeling of the space-time distribution of general secondary messengers and increase the predictive power of biophysical simulations."

New tech for brain damage treatment

Badri Roysam, chair of the University of Houston Department of Electrical and Computer Engineering, is leading the project that uncovering new details surrounding concussions. Photo courtesy of UH Research

Concussions and brain damage have both had their fair shares of question marks, but this UH faculty member is tapping into new technologies to lift the curtain a little.

Badri Roysam, the chair of the University of Houston Department of Electrical and Computer Engineering, is heading up a multimillion-dollar project that includes "super microscopes" and the UH supercomputer at the Hewlett Packard Enterprise Data Science Institute. Roysam calls the $3.19 million project a marriage between these two devices.

"By allowing us to see the effects of the injury, treatments and the body's own healing processes at once, the combination offers unprecedented potential to accelerate investigation and development of next-generation treatments for brain pathologies," says Roysam in a release.

The project, which is funded by the National Institute of Neurological Disorders and Stroke (NINDS), is lead by Roysam and co-principal investigator John Redell, assistant professor at UTHealth McGovern Medical School. The team also includes NINDS scientist Dragan Maric and UH professors Hien Van Nguyen and Saurabh Prasad.

Concussions, which affect millions of people, have long been mysterious to scientists due to technological limitations that hinder treatment options and opportunities.

"We can now go in with eyes wide open whereas before we had only a very incomplete view with insufficient detail," says Roysam in the release. "The combinations of proteins we can now see are very informative. For each cell, they tell us what kind of brain cell it is, and what is going on with that cell."

The technology and research can be extended to other brain conditions, such as strokes, brain cancer, and more.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

4 Houston-area institutions get $8M for cancer research facilities

fighting cancer

Cancer research capabilities in the Houston area just got an $8 million boost.

On Wednesday, May 20, the Cancer Prevention and Research Institute of Texas (CPRIT) awarded $8 million in grants to institutions in Houston and Bryan for the creation or expansion of so-called “core” cancer research facilities.

“Core facilities provide shared access to advanced technology, equipment, and scientific expertise that may not be available at every institution,” CPRIT says. “These core facilities are vital to not only cancer research but also to the study of diseases beyond cancer.”

Houston-area recipients of these $2 million grants are:

  • A facility at the University of Texas Health Science Center for preclinical support of cancer researchers in Texas to evaluate new safe, effective drugs and drug combinations.
  • The Accelerator for Cancer Therapeutics, operated by Houston’s Texas Medical Center Foundation. The accelerator helps researchers and startups move innovative cancer treatments from the lab to clinical trials.
  • Rice University’s Genetic Design & Engineering Center in Houston. The center enables researchers to collaborate on studies of custom DNA for cancer treatment.
  • A facility at the Texas A&M University System’s Health Science Center in Bryan that aims to speed up the development of cancer therapies.

In addition to those grants, the University of Texas M.D. Anderson Cancer Center, Methodist Hospital Research Institute, Baylor College of Medicine, and Rice University shared $21 million to recruit cancer researchers from other institutions.

The largest of those grants—totalling $4 million—went to M.D. Anderson for the recruitment of renowned cancer researcher Andre Nussenzweig from the National Institutes of Health. His research focuses on how DNA damage and faulty DNA repairs lead to cancer.

Here are the totals for the other CPRIT grants awarded in the Houston area:

  • $12.8 million to Houston-based Indapta Therapeutics for the development of an off-the-shelf therapy that naturally kills cancer cells, combined with an immunity-targeting agent for a type of leukemia.
  • $11.1 million to MD Anderson, including $5 million for a statewide platform to improve long-term health outcomes in adolescents and young adults who survived cancer.
  • $8.4 million to Baylor College of Medicine, including $4.8 million for two training programs for cancer researchers.
  • $6.25 million to UT Health Houston, including $4 million for a biomedical informatics and genomics training program for cancer researchers.
  • $4.4 million to the Texas A&M Health Science Center’s Houston campus, including $2.4 million for a cancer therapeutics training program.
  • $2.75 million to Rice, including $250,000 for a study of ovarian cancer.
  • $2 million to Houston-based March Biosciences for the development of a targeted therapy for treating T-cell lymphoma.
  • $1.15 million to the University of Houston, including $900,000 for a platform for detection of lung cancer.
  • $900,000 to Texas A&M in Bryan to conduct clinical drug trials in rural and underserved communities around the state.
  • $800,000 to Houston- and Israel-based Xerient Pharma for the development of an oral form of a cell-protecting drug called amifostine to protect the upper GI tract from radiation damage during pancreatic cancer treatment.
  • $659,000 to Missouri City-based OmniNano Pharmaceuticals for the development of a two-drug combination to treat the most common form of pancreatic cancer.
  • $250,000 to the University of Texas Medical Branch at Galveston for a novel therapeutic to prevent colitis-related colorectal cancer.

Axiom Space launches Japanese subsidiary, names leadership

Axiom Space is setting up a Japanese subsidiary to tap into billions of dollars worth of business opportunities in the vast Asia-Pacific region. The company’s new office in Japan will open July 1.

“For the Asia-Pacific region, an Axiom Space presence in Japan means a long-term, direct path to low-Earth orbit for research, for industry, for astronauts, and a partner committed to building that future together with Japan,” Jonathan Cirtain, president and CEO of Axiom Space, said in a news release.

Asia-Pacific spaceflight leaders include Japan, China, India and South Korea.

Until committing to the Asia-Pacific subsidiary, Axiom focused primarily on the U.S. market for space exploration equipment, technology and services. Axiom is building the successor to the International Space Station (ISS), and it provides human spaceflight services and develops next-generation spacesuits.

Fortune Business Insights estimates the Asia-Pacific market for space technology was valued at $155.3 billion in 2025.

“The region is rapidly expanding due to rapidly expanding government space programs, increasing private sector participation, and rising demand for satellite services across densely populated regions,” says Fortune Business Insights, a market research firm.

The region’s combination of strategic investments, market demand and emerging entrepreneurial systems positions Asia-Pacific “for the fastest growth in the global market,” Fortune Business Insights says.

The market research firm pegs the U.S. market for space technology at $251.8 billion in 2025, making it the world’s largest player in that sector.

Veteran Japanese astronaut Koichi Wakata will lead Axiom Space Japan as chief technology officer in the Asia-Pacific region. The Japanese subsidiary will work with government agencies, research institutions, and industrial partners in Japan to expand hardware development and manufacturing, microgravity research and orbital computing.

Wakata was the Japanese space agency’s first program manager for ISS and the station’s first Japanese commander. He also contributed to the construction of ISS, including the Japanese experiment module Kibo. Wakata retired from the Japanese agency, JAXA, in March 2024.

“Japan intends to remain a leading nation in human space exploration post-ISS, and Japanese industry and academia are ready to play a central role in the commercial era,” Axiom Space said in the release. “Axiom Space Japan is how the company will meet that ambition with a long-term, on-the-ground presence.”

Houston investment firm closes $105M energy venture fund

seeing green

Houston-based investment firm Veriten has announced the initial close of its second flagship energy venture fund with more than $105 million in capital commitments.

Fund II will build on Veriten’s initial fund and aim to support “scalable technology solutions for energy, power and industrial applications,” according to a company news release.

"Our differentiated network, research-driven process, and first principles approach to investing are having an impact across multiple verticals including traditional energy, electrification, and industrial technology. Fund II builds on that platform,” John Sommers, partner, investments at Veriten, added in the release. “In this environment, the differentiator isn't capital – it's all about connectivity, deep sector expertise, and an economically-driven approach. As new technologies and approaches develop at breakneck speed, the need for more reliable, affordable energy and power continues to grow dramatically. The current backdrop accentuates the need for Veriten's solution."

Veriten is supported by over 50 strategic partnerships in the energy, power, industrial and technology sectors, including major players like Halliburton and Phillips 66.

"Veriten continues to build a differentiated platform at the intersection of energy, technology and industry expertise," Jeff Miller, chairman and CEO of Halliburton, said in the release. "We were early believers in the team and their ability to identify practical solutions to real challenges across the energy value chain. As all industries increasingly adopt digital tools, automation and AI-enabled technologies to improve performance and execution, we are proud to partner with Veriten again to help accelerate high-impact solutions across the broader energy landscape."

Veriten closed its debut fund, NexTen LP, of $85 million in committed capital in October 2023. It was launched in January 2022 by Maynard Holt, co-founder and former CEO of the energy investment bank Tudor, Pickering, Holt & Co.

It has invested in Houston-based AI-powered electricity analytics provider Amperon and led a $12 million Seed 2 funding round for Houston-based Helix Technologies to scale manufacturing of its energy-efficient commercial HVAC add-on earlier this year. In the past year it has contributed to funding rounds for San Francisco-based Armada and Calgary-based Veerum.

Veriten also named Nick Morriss as its new managing director earlier this month. Morriss most recently served as vice president of business development at next-generation nuclear technology company Natura Resources and spent nearly 20 years at NOV Inc.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.